Opinion|Videos|January 7, 2025
SPEARHEAD-1: Overview of Study Design, Key Efficacy, and Safety
Panelists discuss how afamitresgene autoleucel (afami-cel) demonstrated meaningful clinical activity in SPEARHEAD-1, with manageable cytokine release syndrome as the main safety concern.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly review the pivotal SPEARHEAD-1 trial that led to afami-cel’s approval.
- Please review study design, key efficacy and safety (
Tine et al, CTOS2022 ). - Please explain the role of targeting MAGE-A4.
Advertisement
Related to this article
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5